-
Je něco špatně v tomto záznamu ?
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial
SD. Solomon, AR. Rizkala, MP. Lefkowitz, VC. Shi, J. Gong, N. Anavekar, SD. Anker, JL. Arango, JL. Arenas, D. Atar, T. Ben-Gal, SA. Boytsov, CH. Chen, VK. Chopra, J. Cleland, J. Comin-Colet, HD. Duengen, LE. Echeverría Correa, G. Filippatos, AJ....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
NLK
Free Medical Journals
od 2008 do Před 1 rokem
Open Access Digital Library
od 2008-05-01
- MeSH
- antagonisté mineralokortikoidních receptorů terapeutické užití MeSH
- antagonisté receptorů pro angiotenzin terapeutické užití MeSH
- beta blokátory terapeutické užití MeSH
- blokátory receptorů AT1 pro angiotensin II terapeutické užití MeSH
- funkce levé komory srdeční účinky léků MeSH
- inhibitory ACE terapeutické užití MeSH
- klinické zkoušky jako téma MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- srdeční selhání farmakoterapie patofyziologie MeSH
- tepový objem účinky léků MeSH
- valsartan terapeutické užití MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: To describe the baseline characteristics of patients with heart failure and preserved left ventricular ejection fraction enrolled in the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in HFpEF) comparing sacubitril/valsartan to valsartan in reducing morbidity and mortality. METHODS AND RESULTS: We report key demographic, clinical, and laboratory findings, and baseline therapies, of 4822 patients randomized in PARAGON-HF, grouped by factors that influence criteria for study inclusion. We further compared baseline characteristics of patients enrolled in PARAGON-HF with those patients enrolled in other recent trials of heart failure with preserved ejection fraction (HFpEF). Among patients enrolled from various regions (16% Asia-Pacific, 37% Central Europe, 7% Latin America, 12% North America, 28% Western Europe), the mean age of patients enrolled in PARAGON-HF was 72.7±8.4 years, 52% of patients were female, and mean left ventricular ejection fraction was 57.5%, similar to other trials of HFpEF. Most patients were in New York Heart Association class II, and 38% had ≥1 hospitalizations for heart failure within the previous 9 months. Diabetes mellitus (43%) and chronic kidney disease (47%) were more prevalent than in previous trials of HFpEF. Many patients were prescribed angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (85%), β-blockers (80%), calcium channel blockers (36%), and mineralocorticoid receptor antagonists (24%). As specified in the protocol, virtually all patients were on diuretics, had elevated plasma concentrations of N-terminal pro-B-type natriuretic peptide (median, 911 pg/mL; interquartile range, 464-1610), and structural heart disease. CONCLUSIONS: PARAGON-HF represents a contemporary group of patients with HFpEF with similar age and sex distribution compared with prior HFpEF trials but higher prevalence of comorbidities. These findings provide insights into the impact of inclusion criteria on, and regional variation in, HFpEF patient characteristics. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01920711.
1st Department of Internal Medicine Nara Medical University Kashihara Japan
1st Faculty of Medicine Charles University Prague Czech Republic
Associazione Nazionale Medici Cardiologi Ospedalieri Florence Italy
Baylor Heart and Vascular Institute Baylor University Medical Center Dallas TX
British Heart Foundation Cardiovascular Research Centre
Cardiology Division Cardiovascular Department Hospital Papa Giovanni XXIII Bergamo Italy
Cardiovascular Division Brigham and Women's Hospital Harvard Medical School Boston MA
Centro de Atención e Investigación Cardiovascular del Potosi SC and Hospital Ángeles San Luis México
Clinic of Cardiology National Cardiology Hospital Sofia Bulgaria
Department of Cardiology B Oslo University Hospital University of Oslo Norway
Department of Cardiology City Hospital Durban South Africa
Department of Cardiology Faculty of Medicine Cumhuriyet University Sivas Turkey
Department of Cardiology Hospital Group Twente Almelo and Hengelo The Netherlands
Department of Cardiology Medical University Graz Austria
Department of Cardiology National Heart Centre Singapore
Department of Cardiology Rangueil University Hospital Toulouse France
Department of Cardiology Tampere University Hospital Finland
Department of Cardiology Tongji Hospital Tongji University School of Medicine Shanghai China
Department of Cardiology University Heart Center Zurich University Hospital Zurich Switzerland
Department of Cardiology University Hospitals Leuven Belgium
Department of Cardiovascular Diseases University Hospital Center Zagreb Croatia
Department of Cardiovascular Medicine Mayo Clinic Rochester MN
Department of Heart Failure Transplantation National Cardiovascular Institute Bratislava Slovakia
Department of Medicine National Yang Ming University Taipei Taiwan Republic of China
Department of Medicine VA Medical Center and University of Minnesota Minneapolis
Department of Noninvasive Cardiology Medical University of Lodz Poland
Division of Cardiology and Metabolism Department of Cardiology
Faculty of Medicine Dentistry and Health Sciences University of Melbourne Australia
Heart and Vascular Center Semmelweis University Budapest Hungary
Heart Failure Unit Cardiology Department Rabin Medical Center Petah Tikva Israel
Heart Failure Unit Medanta Medicity Gurugram Haryana India
Inserm CIC 1433 and Université de Lorraine Centre Hospitalier Ré gional Universitaire Nancy France
Institut de Cardiologie de Montréal Université de Montréal Québec Canada
Instituto FLENI Buenos Aires Argentina
National Heart Centre Singapore and Duke National University of Singapore
Novartis Pharmaceuticals Corporation East Hanover NJ
Sarver Heart Center University of Arizona College of Medicine Tucson
Seoul National University Hospital Seoul National University College of Medicine Korea
Shanghai Institute of Cardiovascular Diseases Zhongshan Hospital Fudan University China
St Luke's Heart Institute St Luke's Medical Center Taguig Philippines
Universidad Nacional of Cordoba Argentina
University Medical Center Groningen University of Groningen The Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19035141
- 003
- CZ-PrNML
- 005
- 20240910103525.0
- 007
- ta
- 008
- 191007s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1161/CIRCHEARTFAILURE.118.004962 $2 doi
- 035 __
- $a (PubMed)29980595
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Solomon, Scott D. $7 xx0243096 $u Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ssolomon@bwh.harvard.edu.
- 245 10
- $a Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial / $c SD. Solomon, AR. Rizkala, MP. Lefkowitz, VC. Shi, J. Gong, N. Anavekar, SD. Anker, JL. Arango, JL. Arenas, D. Atar, T. Ben-Gal, SA. Boytsov, CH. Chen, VK. Chopra, J. Cleland, J. Comin-Colet, HD. Duengen, LE. Echeverría Correa, G. Filippatos, AJ. Flammer, M. Galinier, A. Godoy, E. Goncalvesova, S. Janssens, T. Katova, L. Køber, M. Lelonek, G. Linssen, LH. Lund, E. O'Meara, B. Merkely, D. Milicic, BH. Oh, SV. Perrone, N. Ranjith, Y. Saito, JF. Saraiva, S. Shah, PM. Seferovic, M. Senni, AS. Sibulo, D. Sim, NK. Sweitzer, J. Taurio, D. Vinereanu, B. Vrtovec, J. Widimský, MB. Yilmaz, J. Zhou, R. Zweiker, IS. Anand, J. Ge, CSP. Lam, AP. Maggioni, F. Martinez, M. Packer, MA. Pfeffer, B. Pieske, MM. Redfield, JL. Rouleau, DJ. Van Veldhuisen, F. Zannad, MR. Zile, JJV. McMurray,
- 520 9_
- $a BACKGROUND: To describe the baseline characteristics of patients with heart failure and preserved left ventricular ejection fraction enrolled in the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in HFpEF) comparing sacubitril/valsartan to valsartan in reducing morbidity and mortality. METHODS AND RESULTS: We report key demographic, clinical, and laboratory findings, and baseline therapies, of 4822 patients randomized in PARAGON-HF, grouped by factors that influence criteria for study inclusion. We further compared baseline characteristics of patients enrolled in PARAGON-HF with those patients enrolled in other recent trials of heart failure with preserved ejection fraction (HFpEF). Among patients enrolled from various regions (16% Asia-Pacific, 37% Central Europe, 7% Latin America, 12% North America, 28% Western Europe), the mean age of patients enrolled in PARAGON-HF was 72.7±8.4 years, 52% of patients were female, and mean left ventricular ejection fraction was 57.5%, similar to other trials of HFpEF. Most patients were in New York Heart Association class II, and 38% had ≥1 hospitalizations for heart failure within the previous 9 months. Diabetes mellitus (43%) and chronic kidney disease (47%) were more prevalent than in previous trials of HFpEF. Many patients were prescribed angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (85%), β-blockers (80%), calcium channel blockers (36%), and mineralocorticoid receptor antagonists (24%). As specified in the protocol, virtually all patients were on diuretics, had elevated plasma concentrations of N-terminal pro-B-type natriuretic peptide (median, 911 pg/mL; interquartile range, 464-1610), and structural heart disease. CONCLUSIONS: PARAGON-HF represents a contemporary group of patients with HFpEF with similar age and sex distribution compared with prior HFpEF trials but higher prevalence of comorbidities. These findings provide insights into the impact of inclusion criteria on, and regional variation in, HFpEF patient characteristics. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01920711.
- 650 _2
- $a beta blokátory $x terapeutické užití $7 D000319
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a blokátory receptorů AT1 pro angiotensin II $x terapeutické užití $7 D047228
- 650 _2
- $a antagonisté receptorů pro angiotenzin $x terapeutické užití $7 D057911
- 650 _2
- $a inhibitory ACE $x terapeutické užití $7 D000806
- 650 _2
- $a klinické zkoušky jako téma $7 D002986
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a srdeční selhání $x farmakoterapie $x patofyziologie $7 D006333
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a antagonisté mineralokortikoidních receptorů $x terapeutické užití $7 D000451
- 650 _2
- $a tepový objem $x účinky léků $7 D013318
- 650 _2
- $a valsartan $x terapeutické užití $7 D000068756
- 650 _2
- $a funkce levé komory srdeční $x účinky léků $7 D016277
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Rizkala, Adel R $u Novartis Pharmaceuticals Corporation, East Hanover, NJ
- 700 1_
- $a Lefkowitz, Martin P $u Novartis Pharmaceuticals Corporation, East Hanover, NJ
- 700 1_
- $a Shi, Victor C $u Novartis Pharmaceuticals Corporation, East Hanover, NJ
- 700 1_
- $a Gong, JianJian $u Novartis Pharmaceuticals Corporation, East Hanover, NJ
- 700 1_
- $a Anavekar, Nagesh $u Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Australia
- 700 1_
- $a Anker, Stefan D $u Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) Berlin, Charité Universitätsmedizin Berlin, Germany. Department of Cardiology and Pneumology, University of Göttingen Medical Center, Germany (S.D.A.).
- 700 1_
- $a Arango, Juan L $u Guatemalan Heart Institute
- 700 1_
- $a Arenas, Jose L $u Centro de Atención e Investigación Cardiovascular del Potosi SC and Hospital Ángeles San Luis, México
- 700 1_
- $a Atar, Dan $u Department of Cardiology B, Oslo University Hospital, University of Oslo, Norway
- 700 1_
- $a Ben-Gal, Turia $u Heart Failure Unit, Cardiology Department, Rabin Medical Center, Petah Tikva, Israel
- 700 1_
- $a Boytsov, Sergey A $u National Research Center for Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia
- 700 1_
- $a Chen, Chen-Huan $u Department of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China
- 700 1_
- $a Chopra, Vijay K $u Heart Failure Unit, Medanta Medicity, Gurugram, Haryana, India
- 700 1_
- $a Cleland, John $u Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Wellbeing, University of Glasgow, United Kingdom. National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London, United Kingdom (J.C.). Community Heart Failure Program, Department of Cardiology, Bellvitge University Hospital and Institut d'Investigació Biomèdica de Bellvitge, University of Barcelona, Spain
- 700 1_
- $a Comin-Colet, Josep $u Community Heart Failure Program, Department of Cardiology, Bellvitge University Hospital and Institut d'Investigació Biomèdica de Bellvitge, University of Barcelona, Spain
- 700 1_
- $a Duengen, Hans-Dirk $u National Research Center for Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia
- 700 1_
- $a Echeverría Correa, Luis E $u Department of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China
- 700 1_
- $a Filippatos, Gerasimos $u Attikon University Hospital, National and Kapodistrian University of Athens, Greece (G.F.). School of Medicine, University of Cyprus, Greece
- 700 1_
- $a Flammer, Andreas J $u Department of Cardiology, University Heart Center Zurich, University Hospital Zurich, Switzerland
- 700 1_
- $a Galinier, Michel $u Department of Cardiology, Rangueil University Hospital, Toulouse, France
- 700 1_
- $a Godoy, Armando $u Universidad Nacional Mayor de San Marcos, Lima, Perú (A.G.). Instituto Nacional Cardiovascular INCOR, Lima, Perú (A.G.). Scientia Clinical and Epidemiological Research Institute, Trujillo, Perú
- 700 1_
- $a Goncalvesova, Eva $u Department of Heart Failure/Transplantation, National Cardiovascular Institute, Bratislava, Slovakia
- 700 1_
- $a Janssens, Stefan $u Department of Cardiology, University Hospitals Leuven, Belgium
- 700 1_
- $a Katova, Tzvetana $u Clinic of Cardiology, National Cardiology Hospital, Sofia, Bulgaria
- 700 1_
- $a Køber, Lars $u Department of Cardiology, Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- 700 1_
- $a Lelonek, Małgorzata $u Department of Noninvasive Cardiology, Medical University of Lodz, Poland
- 700 1_
- $a Linssen, Gerard $u Department of Cardiology, Hospital Group Twente, Almelo and Hengelo, The Netherlands
- 700 1_
- $a Lund, Lars H $u Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden
- 700 1_
- $a O'Meara, Eileen $u Institut de Cardiologie de Montréal, Université de Montréal, Québec, Canada
- 700 1_
- $a Merkely, Béla $u Heart and Vascular Center, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Milicic, Davor $u Department of Cardiovascular Diseases, University Hospital Center Zagreb, Croatia
- 700 1_
- $a Oh, Byung-Hee $u Seoul National University Hospital, Seoul National University College of Medicine, Korea
- 700 1_
- $a Perrone, Sergio V $u Instituto FLENI, Buenos Aires, Argentina
- 700 1_
- $a Ranjith, Naresh $u Department of Cardiology, City Hospital, Durban, South Africa
- 700 1_
- $a Saito, Yoshihiko $u First Department of Internal Medicine, Nara Medical University, Kashihara, Japan
- 700 1_
- $a Saraiva, Jose F $u Disciplina de Cardiologia Faculdade de Medicina, Pontifícia Universidade Católica de Campinas, Sao Paulo, Brazil
- 700 1_
- $a Shah, Sanjiv $u Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
- 700 1_
- $a Seferovic, Petar M $u Department of Cardiology, University of Belgrade School of Medicine, Belgrade University Medical Center, Serbia
- 700 1_
- $a Senni, Michele $u Cardiology Division, Cardiovascular Department, Hospital Papa Giovanni XXIII, Bergamo, Italy
- 700 1_
- $a Sibulo, Antonio S $u St Luke's Heart Institute, St. Luke's Medical Center, Taguig, Philippines
- 700 1_
- $a Sim, David $u Department of Cardiology, National Heart Centre Singapore
- 700 1_
- $a Sweitzer, Nancy K $u Sarver Heart Center, University of Arizona College of Medicine, Tucson
- 700 1_
- $a Taurio, Jyrki $u Department of Cardiology, Tampere University Hospital, Finland
- 700 1_
- $a Vinereanu, Dragos $u University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital of Bucharest, Romania
- 700 1_
- $a Vrtovec, Bojan $u University Medical Centre, Ljubljana, Slovenia
- 700 1_
- $a Widimský, Jiří $u First Faculty of Medicine, Charles University Prague, Czech Republic
- 700 1_
- $a Yilmaz, Mehmet B $u Department of Cardiology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey
- 700 1_
- $a Zhou, Jingmin $u Department of Cardiology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China
- 700 1_
- $a Ge, Junbo $u Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China
- 700 1_
- $a Anand, Inder S. $u Department of Medicine, VA Medical Center and University of Minnesota, Minneapolis $7 xx0322272
- 700 1_
- $a Zweiker, Robert $u Department of Cardiology, Medical University Graz, Austria
- 700 1_
- $a Lam, Carolyn S P $u National Heart Centre Singapore and Duke-National University of Singapore
- 700 1_
- $a Maggioni, Aldo P $u Associazione Nazionale Medici Cardiologi Ospedalieri, Florence, Italy
- 700 1_
- $a Martinez, Felipe $u Universidad Nacional of Cordoba, Argentina
- 700 1_
- $a Packer, Milton $u Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX
- 700 1_
- $a Pfeffer, Marc A $u Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
- 700 1_
- $a Pieske, Burkert $u Department of Internal Medicine, Cardiology Charité, Universitaetsmedizin Berlin, Campus Virchow Klinikum Berlin, Germany
- 700 1_
- $a Redfield, Margaret M $u Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN
- 700 1_
- $a Rouleau, Jean L $u Institut de Cardiologie de Montréal, Université de Montréal, Québec, Canada
- 700 1_
- $a Van Veldhuisen, Dirk J $u University Medical Center Groningen, University of Groningen, The Netherlands
- 700 1_
- $a Zannad, Faiez $u Inserm CIC 1433 and Université de Lorraine, Centre Hospitalier Ré gional Universitaire, Nancy, France
- 700 1_
- $a Zile, Michael R $u Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston
- 700 1_
- $a McMurray, John J V $u British Heart Foundation Cardiovascular Research Centre
- 773 0_
- $w MED00159985 $t Circulation. Heart failure $x 1941-3297 $g Roč. 11, č. 7 (2018), s. e004962
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29980595 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20240910103522 $b ABA008
- 999 __
- $a ok $b bmc $g 1451801 $s 1073691
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 11 $c 7 $d e004962 $e - $i 1941-3297 $m Circulation. Heart failure $n Circ Heart Fail $x MED00159985
- LZP __
- $a Pubmed-20191007
